Hudson Bay Capital Management LP Has $244,000 Stake in Halozyme Therapeutics, Inc. $HALO

Hudson Bay Capital Management LP reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 80.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 3,328 shares of the biopharmaceutical company’s stock after selling 13,423 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Halozyme Therapeutics were worth $244,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in HALO. Empowered Funds LLC bought a new position in shares of Halozyme Therapeutics in the 1st quarter valued at approximately $755,000. Acadian Asset Management LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $195,000. PNC Financial Services Group Inc. boosted its position in Halozyme Therapeutics by 8.0% during the second quarter. PNC Financial Services Group Inc. now owns 9,857 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 727 shares during the period. Legal & General Group Plc grew its holdings in Halozyme Therapeutics by 7.5% during the second quarter. Legal & General Group Plc now owns 337,567 shares of the biopharmaceutical company’s stock valued at $17,560,000 after purchasing an additional 23,475 shares during the last quarter. Finally, AXQ Capital LP acquired a new position in Halozyme Therapeutics during the second quarter valued at approximately $385,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 0.9%

Shares of HALO stock opened at $62.86 on Tuesday. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $82.22. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The firm has a market cap of $7.42 billion, a PE ratio of 25.24, a price-to-earnings-growth ratio of 0.26 and a beta of 0.98. The stock has a 50 day moving average of $71.34 and a 200-day moving average of $70.09.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. During the same quarter in the previous year, the business posted $1.26 EPS. The company’s revenue was up 51.6% on a year-over-year basis. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insiders Place Their Bets

In related news, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Helen Torley sold 10,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $70.21, for a total transaction of $702,100.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $53,905,833.80. The trade was a 1.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 90,857 shares of company stock worth $6,500,287 in the last ninety days. Insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on HALO shares. Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday, February 24th. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. The Goldman Sachs Group reissued a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Finally, TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of “Hold” and a consensus price target of $78.56.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.